Drug Profile
GALE 302
Alternative Names: Attenuated E39 peptide vaccine - Sellas Life Sciences Group; E39 prime vaccine - Sellas Life Sciences Group; E39'; E39'-GM-CSF-vaccine - Sellas Life Sciences Group; EIWTFSTKV; FBP-J65; Folate binding protein J65 - Sellas Life Sciences Group; GALE-302; J65Latest Information Update: 08 Jun 2021
Price :
$50
*
At a glance
- Originator San Antonio Military Medical Centre; University of Texas M. D. Anderson Cancer Center
- Developer Sellas Life Sciences Group
- Class Cancer vaccines; Peptide vaccines; Peptides; Stem cell therapies
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Ovarian cancer
Most Recent Events
- 31 Mar 2021 Sellas Life Sciences terminates its license for folate binding protein-E39 targeted cancer vaccine in February 2021
- 01 Dec 2019 Discontinued - Phase-I/II for Breast cancer (Combination therapy, Prevention of relapse, Adjuvant therapy) in USA (Intradermal) (3464169; 9287650)
- 01 Dec 2019 Discontinued - Phase-I/II for Ovarian cancer (Combination therapy, Prevention of relapse, Adjuvant therapy) in USA (Intradermal) (3464169; 9287650)